



Supplementary Figure 7. Genomics analysis of lung cancer patient cohort. Somatic alterations were measured by the targeted hybrid capture next-generation sequencing assay OncoPanel as part of clinical care (1). The Non-Small Cell Lung Cancer (NSCLC) cohort consists of adenocarcinoma (n=21), squamous cell carcinoma (n=7), and other NSCLC (n=4). (A) Comparisons of aneuploidy score, amplifications, deletions, and tumor mutational burden between lung cancer patients with detectable versus undetectable circulating ORF1p levels, as measured by the first-generation ORF1p Simoa assay; p values by Wilcoxon test. KRAS mutations were not identified in the 11 ORF1p-detectable cases. (B) Mutation types and top mutated genes in lung cancer patients with detectable versus undetectable circulating ORF1p.